Literature DB >> 17645916

Neuroleptic malignant syndrome and serotonin syndrome.

Koichi Nisijima1, Katsutoshi Shioda, Tatsunori Iwamura.   

Abstract

This chapter is focused on drug-induced hyperthermia with special regard to use of antipsychotics and antidepressants for the treatment of schizophrenia and major depression, respectively. Neuroleptic malignant syndrome (NMS) develops during the use of neuroleptics, whereas serotonin syndrome is caused mainly by serotoninergic antidepressants. Although both syndromes show various symptoms, hyperthermia is the main clinical manifestation. In this review we describe the historical background, clinical manifestations, diagnosis, and differential diagnosis of these two syndromes based on our observations on the experimental and clinical data.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17645916     DOI: 10.1016/S0079-6123(06)62006-2

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  3 in total

1.  Malignant Syndrome and Serotonin Syndrome in a General Hospital Setting: Clinical Features, Frequency and Prognosis.

Authors:  Akiyuki Hiraga; Satoshi Kuwabara
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

2.  Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome.

Authors:  Koichi Nisijima; Katutoshi Shioda
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-18       Impact factor: 2.570

3.  Two cases of mild serotonin toxicity via 5-hydroxytryptamine 1A receptor stimulation.

Authors:  Hiroto Nakayama; Sumiyo Umeda; Masashi Nibuya; Takeshi Terao; Koichi Nisijima; Soichiro Nomura
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-11       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.